HomeNewsGlobal Pharma

Alterity Therapeutics Raises AUD 2.13 Million from US Market to Accelerate ATH434 Clinical and BD Activities

Alterity Therapeutics Raises AUD 2.13 Million from US Market to Accelerate ATH434 Clinical and BD Activities

Alterity Therapeutics, a biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases, has announced that it raised capital in the US to accelerate clinical development and business development activities for the company’s lead asset, ATH434.

Based on the positive topline results reported on January 30, 2025, from the ATH434-201 Phase 2 trial in multiple system atrophy (MSA), the company was afforded the opportunity to raise capital in the US via its at-the-market (ATM) facility.

In addition to raising approximately AUD 2.13 Million on the ATM, the company expects to receive in Q1 CY2025 approximately AUD 5.69 Million in rebates from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme.

Combined, these proceeds will enable the company to advance its clinical and regulatory activities and to accelerate business development activities for ATH434.

Read more on:
More news about: global pharma | Published by Manvi | February - 03 - 2025

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members